Citius Oncology, Inc. (CTOR)

Citius Oncology Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Dec 31, 2022
Selling, General & Admin	41.61	17.1	15.65	7.88	0.14
Depreciation & Amortization Expenses	2.29	-	-	-	-
Research & Development	4.11	6.42	4.93	4.24	-
Total Operating Expenses	48.02	23.52	20.57	12.12	0.14
Operating Income	-43.52	-23.52	-20.57	-12.12	-0.14
Interest Income	0.09	0.04	-	-	0.49
Interest Expense	0.3	0.22	-	-	-
Other Non-Operating Income (Expense)	1.76	-	-	-	0.03
Total Non-Operating Income (Expense)	2.15	-0.18	-	-	0.52
Pretax Income	-41.95	-23.7	-20.57	-12.12	0.38
Provision for Income Taxes	0.56	1.06	0.58	0.58	-
Net Income	-42.51	-24.76	-21.15	-12.7	0.38
Net Income to Common	-42.51	-24.76	-21.15	-12.7	0.38
Shares Outstanding (Basic)	84	73	68	2	2
Shares Outstanding (Diluted)	84	73	68	2	2
Shares Change (YoY)	20.38%	7.66%	2798.38%	25.86%	-
EPS (Basic)	-0.47	-0.34	-0.31	-0.19	0.12
EPS (Diluted)	-0.47	-0.34	-0.31	-0.19	0.12
Shares Outstanding	92.98	83.51	71.55	2.34	2.42
Free Cash Flow	-16.68	-5.49	0.13	0	-0.05
Free Cash Flow Per Share	-0.20	-0.07	0.00	-	-0.03
EBITDA	-41.23	-23.52	-20.57	-12.12	-0.14
EBIT	-43.52	-23.52	-20.57	-12.12	-0.14
Effective Tax Rate	-1.34%	-4.46%	-2.80%	-4.75%	0.00%

Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q